COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 2 FDA records to the applicant name Lenstec, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 22, 2022 to Oct 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MFK appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P200020, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 1765 Commerce Ave. N, St. Petersburg, FL, 33716. Recorded on P200020/S013, decision dated Oct 23, 2026.
Device categories in this collection
Lens, Multifocal Intraocular.
Changes described in PMA records
The FDA recorded an approval decision on 2026-10-23 for P200020/S013, a supplement to the ClearView™ HD intraocular lens (IOL) held by Lenstec, Inc. The supplement was filed under the Normal 180 Day Track with the stated reason Change Design/Components/Specifications/Material, and the device sits in the multifocal intraocular lens category (product code MFK) within the ophthalmic specialty.
The recorded statement describes the supplement as covering the ClearView™ HD IOL as a combination of the haptic design of the ClearView™ 3 IOL with the optical design of the Softec HD IOL. That describes a design change to the lens rather than a new approval of an entire system. The source record does not include supporting documents, so the specific optical or haptic parameters changed, and any clinical data reviewed, remain unknown.
FDA approval-order wording
approval for the ClearView HD Intraocular Lens (IOL) as a combination of the haptic design of the ClearView 3 IOL with the optical design of the Softec HD IOL
Oct 23, 2026 · Normal 180 Day TrackFDA’s recorded scope: Approval for the Lenstec SBL-3 Multifocal Intraocular Lens. This Lenstec SBL-3 Multifocal Intraocular Lens is indicated for primary implantation for the visual correction of aphakia, in adult patients with 1 diopter or less of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing a bifocal correction. Compared to an aspheric monofocal IOL, the lens provides improved near visual acuity, while maintaining comparable distance and intermediate visual acuity. The lens promotes the less frequent use of vision correction choices at near distance (including glasses, contact lenses, magnifying glasses, and digital adjustments on electronic devices), compared to an aspheric monofocal IOL, as reported in patient-reported outcomes. The SBL-3 multifocal IOL is intended for capsular bag placement only.
Jul 22, 2022Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.